...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of experimental & clinical cancer research : >Detection of disseminated tumour cells as a potential surrogate-marker for monitoring palliative chemotherapy in colorectal cancer patients.
【24h】

Detection of disseminated tumour cells as a potential surrogate-marker for monitoring palliative chemotherapy in colorectal cancer patients.

机译：检测扩散的肿瘤细胞，作为监测大肠癌患者姑息化疗的潜在替代指标。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In a pilot study the effect of palliative chemotherapy on the detection rates of circulating tumour cells in peripheral venous blood of stage IV colorectal cancer patients was investigated. The results indicate a recruitment of tumour cells during chemotherapy and suggest a poorer survival for tumour cell positive patients. Circulating tumour cells have been shown to be a potential prognostic factor in patients who undergo curative resection for colorectal cancer. The effect of chemotherapy on the detection rates of disseminated tumour cells in blood has not yet been adequately investigated. Objective of this pilot-study was to analyze circulating tumour cells in peripheral venous blood of colorectal cancer patients undergoing chemotherapy in order to evaluate its potential value as a surrogate-marker for predicting clinical outcome after chemotherapy. Our hypothesis was that chemotherapy results in a reduction of the detection rates of circulating tumour cells in colorectal cancer patients. Forty-two Stage IV patients were examined at three different time points before and during palliative chemotherapy for the presence of disseminated tumour cells, using a previously described RT-PCR-assay for cytokeratin 20. 80.1% of the patients showed disseminated tumour cells at least once. Before chemotherapy, patients with multi-organ metastases were positive in 62.5%, patients with locally limited disease in only 14.3%. After the first chemotherapy, the detection rates in the latter group increased to 62.5%, for all patients in the same time from 46.3% to 57.5%. Clinical therapy responders showed an increase in the detection rates from 28.5% before to 71.4% after chemotherapy. In contrast, chemotherapy had no effect on tumour cell detection rates of patients with progressive disease (57% before vs. 60% after therapy). Patients with detected circulating tumour cells showed a shorter overall survival than patients without circulating tumour cells (83 vs. 53 weeks). Clinical therapy responders on average lived only 3weeks longer than non-responders. In contrast to the original hypothesis, our data suggest a recruiting of circulating tumour cells during chemotherapy in advanced colorectal cancer. Further investigations are needed to clarify the potential role of circulating tumour cells for monitoring chemotherapy in these patients.
机译：在一项初步研究中，研究了姑息化疗对IV期大肠癌患者外周静脉血液中循环肿瘤细胞检出率的影响。结果表明化疗期间肿瘤细胞的募集，并提示肿瘤细胞阳性患者的生存期较差。循环肿瘤细胞已显示是接受结直肠癌根治性切除术的患者的潜在预后因素。化疗对血液中弥散性肿瘤细胞检出率的影响尚未得到充分研究。这项初步研究的目的是分析接受化疗的结直肠癌患者外周静脉血中的循环肿瘤细胞，以评估其作为预测化疗后临床结局的替代指标的潜在价值。我们的假设是，化疗导致大肠癌患者循环肿瘤细胞的检出率降低。使用先前描述的细胞角蛋白20的RT-PCR测定法，在姑息性化疗之前和期间的三个不同时间点对42例IV期患者进行了检查，其中包括细胞角蛋白20。一旦。化疗前，多器官转移患者阳性率为62.5％，局部疾病患者仅为14.3％。第一次化疗后，后一组的检出率提高到62.5％，所有患者同时从46.3％增至57.5％。临床治疗反应者显示出检出率从化疗前的28.5％提高到化疗后的71.4％。相反，化学疗法对进行性疾病患者的肿瘤细胞检出率没有影响（治疗前为57％，治疗后为60％）。检测到循环肿瘤细胞的患者的总生存期比未循环肿瘤细胞的患者要短（83周对53周）。临床治疗反应者的平均寿命仅比非反应者长3周。与最初的假设相反，我们的数据表明晚期结直肠癌的化疗期间循环肿瘤细胞的募集。需要进一步研究以阐明循环肿瘤细胞在监测这些患者化疗中的潜在作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号